Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa)



Status:Recruiting
Conditions:Blood Cancer, Hematology, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - Any
Updated:3/17/2019
Start Date:December 13, 2017
End Date:November 1, 2023
Contact:Associate Director Clinical Trial Disclosure
Email:clinicaltrialdisclosure@celgene.com
Phone:1-888-260-1599

Use our guide to learn which trials are right for you!

A Phase 2, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

This is an open label, single-arm, multicenter, Phase 2 study to evaluate the efficacy and
safety of bb2121 in subjects with relapsed and refractory multiple myeloma. A leukapheresis
procedure will be performed to manufacture bb2121 chimeric antigen receptor (CAR) modified T
cells. Prior to bb2121 infusion subjects will receive lymphodepleting therapy with
fludarabine and cyclophosphamide.

Anti-myeloma bridging treatment is allowed for disease control while bb2121 is being
manufactured.

Three sites in Japan will be activated in 2019 and will be open for enrollment to patients in
Japan.

Inclusion Criteria:

Eligibility is determined prior to leukapheresis. Subjects must satisfy the following
criteria to be enrolled in the study:

1. Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF).

2. Documented diagnosis of multiple myeloma

- Must have received at least 3 prior MM treatment regimens. Note: induction with
or without hematopoietic stem cell transplant and with or without maintenance
therapy is considered a single regimen.

- Must have undergone at least 2 consecutive cycles of treatment for each regimen,
unless PD was the best response to the regimen.

- Must have received a proteasome inhibitor, an immunomodulatory agent and an
anti-CD38 antibody.

- Must be refractory to the last treatment regimen.

3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

4. Subjects must have measurable disease, including at least one of the criteria below:

- Serum M-protein greater or equal to 1.0 g/dL

- Urine M-protein greater or equal to 200 mg/24 h

- Serum free light chain (FLC) assay: involved FLC level greater or equal to 10
mg/dL (100 mg/L) provided serum FLC ratio is abnormal

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

1. Subjects with known central nervous system involvement with myeloma.

2. History or presence of clinically relevant central nervous system (CNS) pathology.

3. Subjects with active or history of plasma cell leukemia.

4. Subjects with solitary plasmacytomas or non-secretory myeloma without other evidence
of measurable disease

5. Inadequate organ function

6. Ongoing treatment with chronic immunosuppressants

7. Previous history of an allogeneic hematopoietic stem cell transplantation or treatment
with any gene therapy-based therapeutic for cancer or investigational cellular therapy
for cancer or BCMA targeted therapy

8. Evidence of human immunodeficiency virus (HIV) infection.

9. Seropositive for and with evidence of active viral infection with hepatitis B virus
(HBV)

10. Seropositive for and with evidence of active viral infection with hepatitis B virus
(HBV) and Hepatitis C virus (HCV)

11. Subjects with a history of class III or IV congestive heart failure (CHF) or severe
non-ischemic cardiomyopathy, history of stroke, unstable angina, myocardial
infarction, or ventricular arrhythmia within the previous 6 months.

12. Subjects with second malignancies in addition to myeloma if the second malignancy has
required therapy in the last 3 years or is not in complete remission

13. Pregnant or lactating women.

14. Subject with known hypersensitivity to any component of bb2121 productThe presence of
any of the following will exclude a subject from enrollment:

1. Subjects with known central nervous system involvement with myeloma. 2. History or
presence of clinically relevant central nervous system (CNS) pathology.

3. Subjects with active or history of plasma cell leukemia. 4. Subjects with solitary
plasmacytomas or non-secretory myeloma without other evidence of measurable disease 5.
Inadequate organ function 6. Ongoing treatment with chronic immunosuppressants 7. Previous
history of an allogeneic hematopoietic stem cell transplantation or treatment with any gene
therapy-based therapeutic for cancer or investigational cellular therapy for cancer or BCMA
targeted therapy 8. Evidence of human immunodeficiency virus (HIV) infection. 9.
Seropositive for and with evidence of active viral infection with hepatitis B virus (HBV)
and Hepatitis C virus (HCV) 10. Subjects with a history of class III or IV congestive heart
failure (CHF) or severe non-ischemic cardiomyopathy, history of stroke, unstable angina,
myocardial infarction, or ventricular arrhythmia within the previous 6 months. 11. Subjects
with second malignancies in addition to myeloma if the second malignancy has required
therapy in the last 3 years or is not in complete remission 12. Pregnant or lactating
women. 13 Subject with known hypersensitivity to any component of bb2121 product,
cyclophosphamide, fludarabine, or tocilizumab.
We found this trial at
10
sites
1801 Inwood Rd
Dallas, Texas 75390
(214) 645-3300
University of Texas Southwestern Medical Center UT Southwestern is an academic medical center, world-renowned for...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
(404) 727-6123
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
30 Prospect Ave
Hackensack, New Jersey 07601
(201) 996-2000
Hackensack University Medical Center Hackensack University Medical Center, part of the Hackensack University Health Network,...
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Leuven, Flemish Brabant
?
mi
from
Leuven,
Click here to add this to my saved trials
3322 West End Avenue
Nashville, Tennessee 37203
(615)329-SCRI (7274)
Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is a global strategic research organization...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New York, New York 10029
?
mi
from
New York, NY
Click here to add this to my saved trials
Rochester, Minnesota 55905
?
mi
from
Rochester, MN
Click here to add this to my saved trials
San Francisco, California 94143
?
mi
from
San Francisco, CA
Click here to add this to my saved trials